As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Cabozantinib in the first-line treatment of patients with advanced clear-cell renal cell carcinoma.
This review discusses renal cell carcinoma, pharmacological properties, mechanism of action and major studies featuring Cabozantinib. It also provides commentary and recommendations from Dr Laurence Krieger, a Consultant General Physician at Royal North Shore Hospital and Clinical Lecturer with the University of Sydney.
Please login below to download this issue (PDF)